Journal
DIABETES
Volume 64, Issue 2, Pages 587-592Publisher
AMER DIABETES ASSOC
DOI: 10.2337/db14-0656
Keywords
-
Categories
Funding
- Swedish Research Council [K2013-55X-15043, K2011-65X-12219-15-6]
- AFA Insurance
- EXODIAB
- Swedish Diabetes Association
- Swedish Juvenile Diabetes Foundation
- Novo Nordisk Foundation
- Diabetes Wellness Sverige
- Novo Nordisk Fonden [NNF14OC0010935] Funding Source: researchfish
Ask authors/readers for more resources
The retention of endogenous insulin secretion in type 1 diabetes is an attractive clinical goal, which opens possibilities for long-term restoration of glucose metabolism. Mesenchymal stromal cells (MSCs) constitute, based on animal studies, a promising interventional strategy for the disease. This prospective clinical study describes the translation of this cellular intervention strategy to patients with recent-onset type 1 diabetes. Twenty adult patients with newly diagnosed type 1 diabetes were enrolled and randomized to MSC treatment or to the control group. Residual beta-cell function was analyzed as C-peptide concentrations in blood in response to a mixed-meal tolerance test (MMTT) at 1-year follow-up. In contrast to the patients in the control arm, who showed loss in both C-peptide peak values and C-peptide when calculated as area under the curve during the 1st year, these responses were preserved or even increased in the MSC-treated patients. Importantly, no side effects of MSC treatment were observed. We conclude that autologous MSC treatment in new-onset type 1 diabetes constitutes a safe and promising strategy to intervene in disease progression and preserve beta-cell function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available